Histone Deacetylase Inhibitors Antagonize Distinct Pathways to Suppress Tumorigenesis of Embryonal Rhabdomyosarcoma.
Embryonal rhabdomyosarcoma (ERMS) is the most common soft tissue cancer in children. The prognosis of patients with relapsed or metastatic disease remains poor. ERMS genomes show few recurrent mutations, suggesting that other molecular mechanisms such as epigenetic regulation might play a major role...
Main Authors: | Terra Vleeshouwer-Neumann, Michael Phelps, Theo K Bammler, James W MacDonald, Isaac Jenkins, Eleanor Y Chen |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2015-01-01
|
Series: | PLoS ONE |
Online Access: | https://doi.org/10.1371/journal.pone.0144320 |
Similar Items
-
A review of the therapeutic potential of histone deacetylase inhibitors in rhabdomyosarcoma
by: Omar Selim, et al.
Published: (2023-08-01) -
Overactivation of histone deacetylases and EZH2 in Wilms tumorigenesis
by: Chao-Hui Chen, et al.
Published: (2023-09-01) -
Histone Deacetylases and Histone Deacetylase Inhibitors in Neuroblastoma
by: Monica Phimmachanh, et al.
Published: (2020-10-01) -
Embryonal Rhabdomyosarcoma
by: Halder Saswati, et al.
Published: (2001-01-01) -
Embryonal Rhabdomyosarcoma of Testis
by: Gunjan Bhatia, et al.
Published: (2019-11-01)